New Approaches for Treatment of Advanced Extranodal NK/T-Cell Lymphoma

• Published in: Cancer management and research Vol. 14; pp. 401 - 407
• Main Authors: Yi, Wu, Yang, Tianxin, Lin, Sisi, Hao, Rui, Yu, Jin, Wang, Ying, Tong, Xiangming
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01-01-2022; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Apoptosis; Cancer; Care and treatment; Chemotherapy; Clinical trials; Drug resistance in microorganisms; Epstein-Barr virus; extranodal nk/t cell lymphoma; Glycoproteins; Immunotherapy; Killer cells; Kinases; Leukemia; Ligands; Lymphoma; Medical prognosis; Monoclonal antibodies; Non-Hodgkin's lymphomas; pathway; pd-1; Proteins; Radiation therapy; Remission (Medicine); Review; Romidepsin; Stem cell transplantation; T cells; Tumors; Vincristine; China; pathway; PD-1; extranodal NK/T cell lymphoma; immunotherapy
• ISSN: 1179-1322; 1179-1322
• DOI: 10.2147/CMAR.S328846

Extranodal NK/T cell lymphoma (ENKL) is a rare subtype of lymphoma that shows a poor clinical outcome. The most common sites are the nasal cavity, nasopharynx, paranasal sinuses, tonsils and larynx. Because of P-glycoprotein expression on ENKL cells, ENKL is resistant to anthracycline-based chemotherapy. L-asparaginase-based chemotherapy with or without radiotherapy shows promising outcomes for advanced ENKL, but has limited efficacy in relapsed/refractory ENKL. immune-checkpoint inhibitors, histone deacetylase inhibitors, and monoclonal antibodies are being investigated. In this review, we summarize the new treatments for ENKL.